Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.Research Editor
jeffhans@uab.edu • (205) 209-2355Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.
Specific beats include: biochemistry; cell, developmental and integrated biology; microbiology; molecular genetics; neurobiology; pathology; pharmacology and tocixology; Alabama Drug Discovery Alliance; Bill L. Harbert Institute for Innovation and Entrepreneurship.
Such basic research supports the goal of using stem cells in therapy, where an important hurdle is efficient differentiation.
This award from the AABB honors the top paper published in the journal Transfusion.
Inhibition of this microRNA might improve response to newer diabetes drugs, such as Byetta, Victoza, Trulicity, Januvia, Onglyza and Tradjenta.
UAB gets a CDC grant to set up a sentinel surveillance system to track an antibiotic resistant infectious agent responsible for many cases of pneumonia.
Overexpression of CCND2 increased growth and division of grafted heart muscle cells, resulting in better heart function and decreased size of dead tissue.
These results, seen in animal models, represent a potentially novel therapeutic target for the treatment of seizure disorders.
This structure will further explain how the virus infects human cells and how progeny viruses are assembled, and it may be a point of attack to disarm the virus.
Low dietary potassium leads to calcified arteries and aortic stiffness, while increased dietary potassium alleviates those undesirable effects in a mouse model, suggesting dietary potassium may protect against heart disease and death from heart disease in humans.
Researchers study the mechanisms that prevent autoimmune diseases like rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis after an infection.
This knowledge can provide targets in the search for novel bone-loss therapeutics to treat osteoporosis.